Analysis of the difference between imported drugs and domestic drugs and cost-effectiveness of Afatinib

Afatinib is a second-generation EGFR tyrosine kinase inhibitor (TKI), mainly used to treat patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). With the development of domestic and foreign drug approvals and markets, afatinib has been launched in China. At the same time, there are also imported drugs from two different sources: imported original drugs and domestic generic drugs. The differences are mainly reflected in prices, production companies and supply channels.

In the domestic market, afatinib has been included in medical insurance, and patients can purchase it at hospitals or pharmacies designated by the medical insurance, and the price is relatively controllable. Since medical insurance reimbursement policies vary from region to region, patients need to consult their local hospital or pharmacy for specific reimbursement ratios and reimbursement procedures. Afatinib purchased domestically is an original imported drug or a genuine imported drug introduced through domestic enterprises, which ensures the quality and stability of the drug and enjoys medical insurance coverage, which relatively reduces the financial burden on patients.

In foreign markets, afatinib is mainly divided into original drugs and generic drugs. The price of the original version of afatinib in India is about more than 5,000 yuan, while the price of generic drugs in countries such as India, Laos and Bangladesh is more affordable, usually ranging from a few hundred to more than 2,000 yuan. It should be noted that although generic drugs are low in price, their active ingredients are basically the same as the original drugs, their efficacy is similar, and they meet relevant drug quality standards.

From the perspective of cost-effectiveness, domestic patients choose the original afatinib drug covered by medical insurance because of its advantages such as high drug safety, guaranteed quality, and convenient use; while in foreign markets, generic drugs are low-priced and more suitable for patients who purchase at their own expense or have limited budgets. Generally speaking, patients need to comprehensively consider price, medical insurance reimbursement, drug sources and personal financial situation when choosing drugs to achieve a balance between therapeutic effect and economic burden.

Reference materials:https://www.drugs.com/